HNSA · Hansa Biopharma AB
36.20
SEKUnlock stock Insights
Create a free account to unlock price targets, recommendations, and commentary.
Overview
Market Cap
kr3.73B
PE
0.00
EV/EBITDA
N/A
DIV Yield
0%
Payout Ratio
0%
MQV Rating
1Very Strong
As at 21/09/2026 12:00:00 AM
Price Chart
Description
- All-Companies
- All-Consensus
- HALO 200
- HALO All
- HALO Capital Efficiency
- HALO Consensus Value
- HALO GARP
- HALO Growth
- HALO MQV
- HALO MQV SMALL
- HALO Small
Key Fundamentals
EPS 3 yr Growth
-51.60%
EBITDA Margin
-217.70%
Operating Cashflow
-kr549m
Free Cash Flow Return
-92.60%
ROIC
-90.10%
Interest Coverage
-3.90
Quick Ratio
1.90
Performance
52 weeks range
Low 23.52 - 48.22
Trade Value (12mth)
US$502,891.00
1 week
-9.58%
1 month
-12.27%
YTD
11.99%
1 year
19.28%
All time high
349.40
Additional Data
Shares Outstanding (Fully Diluted)
100m
HALO Sector
Healthcare
Next Company Report Date
04-Feb-27
Next Ex Dividend Date
N/A
Next Dividend Pay Date
N/A
Reporting Currency
SEK
Short Sell (% of issue)
0.00
Health Scores
Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
Mqv
Very Strong
Garp
Very Strong
Mqv Small
Very Strong
Momentum
Price
Very Weak
Earnings
Strong
Growth
Earnings
Very Strong
Dividends
Very Weak
Quality
Capital Efficiency
Very Strong
Balance Sheet
Neutral
Valuation
Value
Consensus
Yield
News & Announcements
No announcements available.
Key Stakeholders
| Name | Title |
| NovaQuest Capital Management LLC | Private Company |
| Theodor Jeansson | Individual |
| Thomas Olausson | Individual |
| Hansa Biopharma AB | Public Company |
| Jonas Wikström | Individual |
